GNG12 as A Novel Molecular Marker for the Diagnosis and Treatment of Glioma

作者：Runze Liu, Zhendong Liu, Yaoye Zhao, Xingbo Cheng, Binfeng Liu, Yanbiao Wang, Jialin Wang, Xiaoyu Lian, Yongjie Zhu, Yanzheng Gao · 发表于：Frontiers in Oncology · 年份：2022 · DOI：10.3389/fonc.2022.726556 · 被引用次数：14 · 研究领域：Glioma Diagnosis and Treatment、Microtubule and mitosis dynamics、Glycosylation and Glycoproteins Research

Purpose GNG12 influences a variety of tumors; however, its relationship with glioma remains unclear. The aim of this study was to comprehensively investigate the relationship between GNG12 and the clinical characteristics and prognosis of glioma patients and reveal the mechanisms causing the malignant process of GNG12. Materials and Methods We obtained information on clinical samples from multiple databases. The expression level of GNG12 was validated using a RT-qPCR and IHC. KM curves were used to assess the correlation between the GNG12 expression and OS of glioma patients. An ROC curve was drawn to assess the predictive performance of GNG12. Univariate and multivariate Cox analyses were performed to analyze the factors affecting the prognosis of patients with glioma. GSEA and TIMER databases were used to estimate the relationship between GNG12 expression, possible molecular mechanisms, and immune cell infiltration. CMap analysis was used to screen candidate drugs for glioma. Subsequent in vitro experiments were used to validate the proliferation and migration of glioma cells and to explore the potential mechanisms by which GNG12 causes poor prognosis in gliomas. Results GNG12 was overexpressed in glioma patients and GNG12 expression level correlated closely with clinical features, including age and histological type, etc. Subsequently, the K-M survival analysis indicated that the expression level of GNG12 was relevant to the prognosis of glioma, and the ROC curve implied t...